209 related articles for article (PubMed ID: 18613801)
1. The cardiovascular safety of rosiglitazone.
Ajjan RA; Grant PJ
Expert Opin Drug Saf; 2008 Jul; 7(4):367-76. PubMed ID: 18613801
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
Starner CI; Schafer JA; Heaton AH; Gleason PP
J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
[TBL] [Abstract][Full Text] [Related]
3. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
Taylor C; Hobbs FD
Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
6. [Therapy with glitazones--a risk for cardiovascular disease?].
Rottlaender D; Michels G; Erdmann E; Hoppe UC
Dtsch Med Wochenschr; 2007 Dec; 132(49):2629-32. PubMed ID: 18050028
[TBL] [Abstract][Full Text] [Related]
7. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone and cardiovascular risk.
Kaul S; Diamond GA
Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
[TBL] [Abstract][Full Text] [Related]
10. The safety of rosiglitazone in the treatment of type 2 diabetes.
Singh S; Loke YK
Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk and TZD: safe therapy for the elderly?
Burt R; Townsend S; Armor B
Consult Pharm; 2009 May; 24(5):392-4. PubMed ID: 19555148
[TBL] [Abstract][Full Text] [Related]
12. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.
Mendes D; Alves C; Batel-Marques F
Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1259-70. PubMed ID: 26376779
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
14. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
15. The safety of thiazolidinediones.
Tolman KG
Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501
[TBL] [Abstract][Full Text] [Related]
16. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
Loke YK; Kwok CS; Singh S
BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
[TBL] [Abstract][Full Text] [Related]
17. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
Betteridge DJ
Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
[TBL] [Abstract][Full Text] [Related]
18. Effects of thiazolidinediones beyond glycaemic control.
Kalaitzidis RG; Sarafidis PA; Bakris GL
Curr Pharm Des; 2009; 15(5):529-36. PubMed ID: 19199979
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
Doggrell SA
Expert Opin Pharmacother; 2008 Feb; 9(3):405-20. PubMed ID: 18220491
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
